Design, Rationale, Methodology, and Aims of a Greek Prospective Idiopathic Pulmonary Fibrosis Registry: Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF)

被引:6
作者
Bouros, Demosthenes [1 ]
Daniil, Zoe [2 ]
Papakosta, Despoina [3 ]
Antoniou, Katerina M. [4 ]
Markopoulou, Katerina [5 ]
Kolilekas, Likurgos [6 ,7 ]
Konstantopoulos, George [8 ]
Papiris, Spyros [9 ]
机构
[1] Natl & Kapodistrian Univ Athens, Acad Dept Pneumonol 1, Hosp Dis Chest Sotiria, Med Sch, Athens, Greece
[2] Univ Thessaly, Resp Med Dept, Sch Med, Univ Hosp Larissa, Larisa, Greece
[3] Aristotle Univ Thessaloniki, Gen Hosp Thessaloniki G Papanikolaou, Pulm Med Dept, Med Sch, Thessaloniki, Greece
[4] Univ Hosp Heraklion, Thorac Med Dept, Iraklion, Greece
[5] Gen Hosp Thessaloniki G Papanikolaou, NHS Pulmonol Dept, Thessaloniki, Greece
[6] Hosp Dis Chest Sotiria, NHS Pulm Dept 7, Athens, Greece
[7] Hosp Dis Chest Sotiria, Asthma Ctr, Athens, Greece
[8] BI Hellas, Med Dept, Athens, Greece
[9] Natl & Kapodistrian Univ Athens, Attikon Gen Hosp, Resp Med Dept 2, Med Sch, Athens, Greece
关键词
Greece; Idiopathic pulmonary fibrosis registry; INDULGE IPF; IPF; INTERSTITIAL LUNG-DISEASES; QUALITY-OF-LIFE; CLINICAL-PRACTICE; PHASE-3; TRIAL; PIRFENIDONE; NINTEDANIB; EPIDEMIOLOGY; EFFICACY; MANAGEMENT; MORTALITY;
D O I
10.1159/000487244
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown origin. Despite the fact that the guidelines on the diagnosis and management of the disease were updated in 2015, incorporating novel agents recently introduced in the therapeutic approach of IPF, there is a lack of data on the epidemiology, disease status, and treatment in clinical practice. Contemporary data provided by national registries in IPF provide valuable information to guide clinical management of the disease in the real-world setting, adjusted to the local needs. Objective: Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF) is a Greek observational registry aiming at gaining further knowledge on the characteristics, management, progression, and outcomes of patients with IPF treated under real-world, clinical practice conditions in Greece. Methods: Approximately 300 patients will be enrolled consecutively in seven reference centers, constituting the largest IPF registry ever established in Greece. Conclusion: This registry is expected to provide data on the characteristics of IPF patients in Greece and the entire clinical management during the course of the disease. (C) 2018 S. Karger AG, Basel
引用
收藏
页码:41 / 47
页数:7
相关论文
共 40 条
[1]  
Anto J M, 2001, Eur Respir J Suppl, V32, p101s
[2]   Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry [J].
Behr, Juergen ;
Hoeper, Marius M. ;
Kreuter, Michael ;
Klotsche, Jens ;
Wirtz, Hubert ;
Pittrow, David .
BMJ OPEN RESPIRATORY RESEARCH, 2013, 1 (01)
[3]   Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry [J].
Behr, Juergen ;
Kreuter, Michael ;
Hoeper, Marius M. ;
Wirtz, Hubert ;
Klotsche, Jens ;
Koschel, Dirk ;
Andreas, Stefan ;
Claussen, Martin ;
Grohe, Christian ;
Wilkens, Henrike ;
Randerath, Winfried ;
Skowasch, Dirk ;
Meyer, F. Joachim ;
Kirschner, Joachim ;
Glaeser, Sven ;
Herth, Felix J. F. ;
Welte, Tobias ;
Huber, Rudolf Maria ;
Neurohr, Claus ;
Schwaiblmair, Martin ;
Kohlhaeufl, Martin ;
Hoeffken, Gert ;
Held, Matthias ;
Koch, Andrea ;
Bahmer, Thomas ;
Pittrow, David .
EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (01) :186-196
[4]   Pharmacological management of IPF [J].
Borie, Raphael ;
Justet, Aurelien ;
Beltramo, Guillaume ;
Manali, Effrosyni D. ;
Pradere, Pauline ;
Spagnolo, Paolo ;
Crestani, Bruno .
RESPIROLOGY, 2016, 21 (04) :615-625
[5]   Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis [J].
Chaudhary, N. I. ;
Roth, G. J. ;
Hilberg, F. ;
Mueller-Ouernheim, J. ;
Prasse, A. ;
Zissel, G. ;
Schnapp, A. ;
Park, J. E. .
EUROPEAN RESPIRATORY JOURNAL, 2007, 29 (05) :976-985
[6]   Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts [J].
Conte, Enrico ;
Gili, Elisa ;
Fagone, Evelina ;
Fruciano, Mary ;
Iemmolo, Maria ;
Vancheri, Carlo .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 58 :13-19
[7]   Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis [J].
Cottin, Vincent ;
Maher, Toby .
EUROPEAN RESPIRATORY REVIEW, 2015, 24 (135) :58-64
[8]   THE EPIDEMIOLOGY OF INTERSTITIAL LUNG-DISEASES [J].
COULTAS, DB ;
ZUMWALT, RE ;
BLACK, WC ;
SOBONYA, RE .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 150 (04) :967-972
[9]  
Coward William R, 2010, Ther Adv Respir Dis, V4, P367, DOI 10.1177/1753465810379801
[10]  
DOUBKOVA M, 2017, CLIN RESP J